EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Targeted next-generation sequencing–based mutational signature analysis in endometrial cancer: utility and limitations across molecular subtypes

Uijin Kim, Ahwon Lee, Keun Ho Lee, Sung Jong Lee, Sook Hee Hong, Donghyuk Lee, Jun Kang, Miseon Lee

Journal of Pathology and Translational Medicine · 15.11.2026 · 60 (6) · 625-634

DOI: 10.4132/jptm.2026.09.07 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pathology and Translational Medicine, erschienen am 15.11.2026. Verfasst von Uijin Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Uijeongbu St. Mary's Hospital, Uijeongbu St. Mary’s Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Molecular subtype classification is essential for staging endometrial cancer, planning adjuvant treatments, and stratifying prognosis. However, the correlation between mutational signature analysis using tumor-only targeted next-generation sequencing (NGS) data and molecular subtypes, as well as the interpretive value at the individual case level, remains inadequately characterized.

Methods

We performed mutational signature analysis on tumor-only targeted NGS data from 72 endometrial cancer cases using the SATS R package. Molecular classification into four subtypes (POLE-mutated, mismatch repair deficient [MMRd], TP53-mutant, and no specific molecular profile [NSMP]) was established through a standard stepwise algorithm that integrated NGS and immunohistochemistry.

Results

Out of the 72 endometrial cancers, 12 were classified as POLE-mutated, 10 as MMRd, six as TP53-mutant, and 44 as NSMP. All POLE-mutated tumors exhibited POLE-associated signatures (SBS10a/SBS10b), including cases with non-hotspot POLE exonuclease variants and tumor mutation burdens below the conventional ultramutation threshold. MMRd-associated signatures showed a broader distribution across molecular subtypes; while the summed MMRd-associated signatures were typically higher in MMRd tumors, low-level contributions were also noted in subsets of NSMP and TP53-mutant tumors. Within the POLE-mutated group, MMRd-associated signatures were more pronounced in cases displaying subclonal MMR protein loss as determined by immunohistochemistry.

Conclusions

In this small, clinically selected cohort, targeted NGS-based mutational signatures provided exploratory, complementary information regarding POLE-associated mutagenesis and mixed MMR-related patterns. Overlapping signature distributions, dependence on the analytical pipeline, and the use of tumor-only targeted sequencing limit case-level interpretation. Mutational signature analysis should be interpreted in conjunction with established molecular tests and should not be used as a stand-alone classifier.

Schlagwörter

Stichwörter der Autor:innen

DNA mismatch repairDNA polymerase IIEndometrial neoplasmsHigh-throughput nucleotide sequencingMicrosatellite instability

Autor:innen und Institutionen

  • Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Cancer Research Institute, The Catholic University of Korea, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Division of Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Department of Statistics, Pusan National University, Busan, Korea.
  • Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. jkang@catholic.ac.kr.

Förderung

  • Uijeongbu St. Mary's Hospital
  • Uijeongbu St. Mary’s Hospital

Zitieren

APA

Kim, U., Lee, A., Lee, K. H., Lee, S. J., Hong, S. H., Lee, D., Kang, J., & Lee, M. (2026). Targeted next-generation sequencing–based mutational signature analysis in endometrial cancer: utility and limitations across molecular subtypes. Journal of Pathology and Translational Medicine, 60(6), 625-634. https://doi.org/10.4132/jptm.2026.09.07

Vancouver

Kim U, Lee A, Lee KH, Lee SJ, Hong SH, Lee D, et al. Targeted next-generation sequencing–based mutational signature analysis in endometrial cancer: utility and limitations across molecular subtypes. Journal of Pathology and Translational Medicine. 2026;60(6):625-634. doi:10.4132/jptm.2026.09.07

BibTeX
@article{Kim2026,
  author = {Kim, Uijin and Lee, Ahwon and Lee, Keun Ho and Lee, Sung Jong and Hong, Sook Hee and Lee, Donghyuk and Kang, Jun and Lee, Miseon},
  title = {Targeted next-generation sequencing–based mutational signature analysis in endometrial cancer: utility and limitations across molecular subtypes},
  journal = {Journal of Pathology and Translational Medicine},
  year = {2026},
  volume = {60},
  number = {6},
  pages = {625--634},
  doi = {10.4132/jptm.2026.09.07}
}
Kostenlos starten →